Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Montelukast (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms BUENA
  • Sponsors IntelGenx Corp.
  • Most Recent Events

    • 27 Nov 2018 According to an IntelGenx media release, company Begins Dosing in Patients.
    • 25 Sep 2018 According to an IntelGenx media release, two research sites (the Centre for Memory and Aging in Toronto, ON and True North Clinical Research in Halifax, NS) are being activated and will be open for patient enrolment as of September 26, 2018, with additional sites planning to initiate patient screening in the near future.
    • 15 Aug 2018 Planned End Date changed from 19 Oct 2019 to 19 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top